RNAC · Cartesian Therapeutics, Inc.
Market Cap
$290.60M
Shares
30.26M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$2.8M
-92.8%
FY2025
Net Income
-$130.3M
-68.3%
FY2025
Operating Margin
-5127.1%
-5014.3pp
FY2025
Diluted EPS
-$5.02
-11.8%
FY2025
Operating Cash Flow
-$73.94M
-212.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.48M | $2.8M | $38.91M | $26M | $110.78M | $85.08M | $16.6M | $6.68M | $903K | $207K | $8.08M | $6.01M | $3.04M | |
| $68.39M | $58.03M | $45.11M | $71.26M | $72.38M | $68.74M | $54.51M | $42.74M | $47.69M | $45.17M | $29.7M | $22.98M | $10.49M | |
| $31.75M | $31.47M | $30.13M | $40.45M | $23.86M | $20.94M | $18.91M | $16.39M | $18.24M | $18.83M | $13.05M | $8.34M | $7.95M | |
| — | $0 | $798K | $6.43M | — | — | — | — | — | — | — | — | — | |
| $156.84M | $146.2M | $82.81M | $112.42M | $96.24M | $89.67M | $73.42M | $59.13M | $65.93M | $63.99M | $42.75M | $31.32M | $18.44M | |
| -$155.36M | -$143.41M | -$43.9M | -$86.42M | $14.54M | -$4.6M | -$56.82M | -$52.46M | -$65.02M | -$63.78M | -$34.67M | -$25.3M | -$15.4M | |
| — | -5127.1% | -112.81% | -332.32% | 13.12% | -5.4% | -342.36% | -785.61% | -7200.66% | -30813.53% | -428.92% | -420.96% | -506.55% | |
| — | — | $0 | $2.83M | $3.03M | $2.84M | $1.56M | $1.52M | $1.49M | $1.21M | $1.25M | $948K | $552K | |
| — | $6.58M | $7.39M | $4.96M | — | — | — | — | — | — | — | — | — | |
| -$5.73M | $3.91M | -$33.24M | $691K | $330K | $15K | $89K | -$1.31M | $10K | -$152K | $4000 | -$26K | -$44K | |
| — | -$139.5M | -$77.14M | -$238.71M | $34.77M | -$9.72M | -$68.88M | -$55.35M | — | — | — | — | — | |
| — | -$9.19M | $287K | -$19M | -$609K | $15.97M | $0 | $0 | — | — | — | — | — | |
| -$151.89M | -$130.3M | -$77.42M | -$219.71M | $35.38M | -$25.69M | -$68.88M | -$55.35M | -$65.34M | -$65.32M | -$36.21M | -$25.17M | -$12.88M | |
| — | -4658.63% | -198.97% | -844.91% | 31.94% | -30.19% | -414.99% | -828.97% | -7235.44% | -31556.04% | -447.98% | -418.8% | -423.68% | |
| — | -$130.3M | -$77.42M | -$257.26M | $35.38M | -$25.69M | -$68.88M | -$55.35M | -$65.34M | -$65.32M | -$40.78M | -$32.51M | -$16.37M | |
| -$151.92M | -$130.26M | -$77.45M | -$219.75M | $35.39M | -$25.69M | -$68.92M | -$55.32M | -$65.47M | -$65.22M | -$35.74M | -$26.28M | -$16.16M | |
| USD/shares | -$5.84 | -$5.02 | -$4.48 | -$49.76 | $7.20 | -$6.60 | -$20.40 | -$36.60 | — | — | — | — | — |
| USD/shares | -$5.84 | -$5.02 | -$4.49 | -$49.76 | $3.00 | -$6.60 | -$20.40 | -$36.60 | — | — | — | — | — |
| shares | — | 25.97M | 17.28M | 5.17M | 4.83M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.8K | 71.68K | 69.69K |
| shares | — | 25.97M | 17.36M | 5.17M | 4.86M | 3.81M | 3.37M | 1.52M | 746.31K | 680.83K | 349.8K | 71.68K | 69.69K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 11.54×
Peer medians compare against the 298 similar-size Biotechnology companies (of 497 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating Segment | $2,797,000 | $38,913,000 | — |
| Reporting Segments | — | — | $26,004,000 |
By Product & Service (USD)
| Component | FY2019 |
|---|---|
| Grant | $100,000 |
Key facts
CIK
1453687
CUSIP
816212302
13F (30d)
79 filings
78 filers
Visit website
Investor relations